{
  "cells": [
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "3C-8Cd2n9gKf"
      },
      "source": [
        "**Target Trial Emulation for the effect of Vasopressors in mortality and organ dysfunction in patients with traumatic hemorrhagic shock**\n",
        "\n",
        "\n",
        "**Background and rationale**\n",
        "\n",
        "- Vasopressor use in severely injured trauma patients has been discouraged due to concerns that vasoconstriction will worsen organ perfusion and result in increased mortality and organ failure in hypotensive trauma patients.\n",
        "- Early observational data showed higher odds of death among patients receiving vasopressors. SR 2017 - unadjusted RR from 2.31 to 7.39, but unable to provide conclusions due to high risk of bias: patients who received vasopressors were systematically sicker than patients treated without vasopressors. One clinical trial (n=78) was too imprecise to yield meaningful results. (BMJ)\n",
        "- A large nationwide cohort study in Japan in 2018 including 3,551 patients found that vasopressor use was independently associated with increased in-hospital mortality after adjustment for confounders (OR 2.168; 95% C, 1.442-3.320),using a propensity score-matched cohort.\n",
        "- Recent  pathophysiology findings show that initial vasoconstriction evolves into a second sympathoinhibitory phase marked by diminished catecholamine effect and depletion of neurohormonal stores. The loss of vasomotor tone results in progressive hypotension and impaired perfusion, a state in which arterial pressure may not be restored even after blood volume replacement.\n",
        "- Current European guidelines recommend the use of vasopressors when restrictive fluid therapy fails to achieve a target arterial pressure of SBP â‰¥80 mmHg to maintain tissue perfusion.\n",
        "\n",
        "Ideally, large multicenter RCT. However, it is difficult given emergent situations and ethical constraints of restricting vasopressors in hypotensive patients. ðŸ¡ª Target Trial Emulation\n",
        "\n",
        "\n",
        "**Eligibility criteria**\n",
        "\n",
        "Inclusion Criteria\n",
        "\n",
        "- Adult Patients (Age â‰¥ 18 years old) admitted to ED â€“ TBD if inclusion from 14yo\n",
        "\n",
        "- Hypotension (SBP <90mmH) at Triage or during ED stay â€“ TBD if <80mmHg\n",
        "\n",
        "- Traumatic Mechanism of Injury (Blunt or penetrating)\n",
        "\n",
        "- Suggestive of Hemorrhagic shock and need for Transfusion â€“ possible to assess???\n",
        "\n",
        "Exclusion Criteria\n",
        "\n",
        "- Spinal Injury (as the cause of shock)\n",
        "\n",
        "- Tension Pneumothorax (as the cause of shock)\n",
        "\n",
        "- Received vasopressors or transfusion before arrival at ED -- proxy for this?\n",
        "\n",
        "- Cardiac arrest\n",
        "\n",
        "- Comfort care prior to trauma\n",
        "\n",
        "- Bite, iatrogenic injuries, anaphylactic\n",
        "\n",
        "**Intervention**\n",
        "\n",
        "- Intervention arm: Use of any vasopressor in the Emergency Department (Bolus or infusion).\n",
        "\n",
        "    - Vasopressors: Norepinephrine, Vasopressin, Dopamine, Epinephrine, Phenylephrine, Levophed, Adrenalin, neosynephrine\n",
        "\n",
        "- Control group: No use of vasopressors in the ED\n",
        "\n",
        "\n",
        "**Outcomes**\n",
        "\n",
        "Primary Outcome: All-cause In-hospital Mortality\n",
        "--TBD : Composite outcome with Mortality & Organ Failure\n",
        "\n",
        "Secondary Outcomes\n",
        "\n",
        "- Organ Failure\n",
        "  - Duration of vital support (vasoactives, mechanical ventilation, and kidney replacement therapy) truncated at day 28.\n",
        "  - SOFA-1 and SOFA-2 scores\n",
        "- Transfusion Need\n",
        "  - Cumulative volume of blood product transfused within 48 hours\n",
        "- Fluid Balance\n",
        "  - Total volume of crystalloids transfused within 48h\n",
        "  - Overall fluid balance at 48h\n",
        "- Total vasopressor requirement within 48 hours\n",
        "- 30-day mortality â€“probably not available\n",
        "- Length of Stay\n",
        "\n",
        "\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "4Za8Nc8Gfaot"
      },
      "outputs": [],
      "source": []
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "TR062QHVfHfX"
      },
      "outputs": [],
      "source": []
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "1HYHfy2efRjb"
      },
      "source": [
        "# New Section"
      ]
    }
  ],
  "metadata": {
    "colab": {
      "provenance": []
    },
    "kernelspec": {
      "display_name": "Python 3",
      "name": "python3"
    },
    "language_info": {
      "name": "python"
    }
  },
  "nbformat": 4,
  "nbformat_minor": 0
}
